57th ASH Annual Meeting and Exposition (December 5-8, 2015): 635. Myeloproliferative Syndromes: Basic Science: Poster I

Myeloproliferative Syndromes: Basic Science Oral and Poster Abstracts
Poster

Hall A, Level 2 (Orange County Convention Center)

Whole Exome Sequencing Reveals Clonal Evolution of Myeloproliferative Neoplasms to Acute Myeloid Leukemia

Jelena D Milosevic Feenstra, PhD¹^*, Elisa Rumi, MD²^*, Daniela Pietra, PhD²^*, Andreas Schönegger¹^*, Christoph Bock, PhD¹^*, Mario Cazzola, MD^2,3 and Robert Kralovics, PhD^1,4

¹CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
²Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
³Department of Molecular Medicine, University of Pavia, Pavia, Italy
⁴Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria

1627

A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis

Paola Guglielmelli, MD, PhD^1,2^*, Giada Rotunno, MSc^1,2^*, Tiziana Fanelli, MSc²^*, Annalisa Pacilli, PhD^1,2^*, Laura Calabresi, BiSci^1,2^*, Alessandro Pancrazzi, BS^1,2^* and Alessandro M. Vannucchi^1,2

¹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
²CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy

1628

Elongation of MPL Transmembrane Domain Is a Novel Activating-Mutation in Essential Thrombocythemia

Yukiya Yamamoto, MD, PhD¹, Sachiko Iba¹^*, Akihiro Abe, MD, PhD¹ and Nobuhiko Emi, MD, PhD²

¹Department of Hematology, Fujita Health University, Toyoake, Japan
²Division of Hematology, Fujita Health University, Toyoake, Japan

1629

Genetic HSC Variability Determines the Drivers of Chronic and Acute Phases of Primary Myelofibrosis

Ioanna N Triviai, PhD¹^*, Silke Zeschke¹^*, Marios Spanakis, PhD²^*, Carol Stocking, PhD³ and Nicolaus Kroeger, M.D.¹

¹Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
²Computational Biomedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology Hellas, Heraklion, Greece
³Heinrich-Pette-Institut, Leibniz Institute of Experimental Hematology, Hamburg, Germany

1630

JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment

Annalisa Pacilli, PhD^1,2^*, Paola Guglielmelli, MD, PhD^1,2^*, Tiziana Fanelli, MSc²^*, Alessandro Pancrazzi, BS^1,2^*, Lisa Pieri, MD, PhD^1,2^*, Rajmonda Fjerza, MD^1,2^* and Alessandro M. Vannucchi^1,2

1631

Cooperative Activity of BRAF F595L and Mutant HRAS in Histiocytic Sarcoma Provides New Insights into Oncogenic BRAF Signaling

Maximilian Kordes¹^*, Michael Röring²^*, Christoph Heining¹^*, Sandra Braun²^*, Barbara Hutter³^*, Daniela Richter¹^*, Christina Geörg¹^*, Claudia Scholl¹, Wilfried Roth⁴^*, Andreas Rosenwald, MD⁵^*, Eva Geissinger⁵^*, Christof von Kalle¹^*, Dirk Jäger¹^*, Benedikt Brors³^*, Wilko Weichert⁴^*, Carsten Grüllich¹^*, Hanno Glimm¹, Tilman Brummer, PhD⁶^* and Stefan Fröhling¹

¹National Center for Tumor Diseases, Heidelberg, Germany
²University of Freiburg, Freiburg, Germany
³German Cancer Research Center, Heidelberg, Germany
⁴Heidelberg University Hospital, Heidelberg, Germany
⁵University of Würzburg, Würzburg, Germany
⁶ALU Freiburg, Signal Transduction in Tumour Development and Drug Resistance Group, Institute of Molecular Medicine and Cell Research (IMMZ), Freiburg, Germany

1632

A Blunted Response to the Anti-Inflammatory Cytokine IL-10 Contributes to Excessive TNF Production in Myeloproliferative Neoplasm

Hew Yeng Lai, BS¹^*, Sarah J Morse, MS, BS¹^*, Thanh Kim Nguyen, MS PhD¹^*, Samuel B Luty, BS²^*, Michael Garbati, PhD, BS³^*, Grover C. Bagby Jr., MD, MACP³, Brian J. Druker, MD⁴ and Angela G Fleischman, MD PhD¹

¹Division of Hematology/Oncology, University of California, Irvine, Irvine, CA
²Knight Cancer Institute, Oregon and Health and Science University, Portland, OR
³Oregon Health & Science University, Portland, OR
⁴Knight Cancer Institute, Oregon Health & Science University, Portland, OR

1633

Novel Mechanisms of Growth Inhibition By Histone Deacetylase Inhibitors in MPN

Ruchi Pandey, Ph.D.¹^*, Raghuveer Mali, PhD²^*, Baskar Ramdas, Ph.D.³^* and Reuben Kapur, Ph.D.¹

¹Indiana University School of Medicine, Indianapolis, IN
²Indiana University School of Medicine Herman B Wells Center for Pediatric Resear, Indianapolis, IN
³Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN

1634

Mpl Gain-of-Function Mutations Can be Classified By Differential Subcellular Processing, Molecular Mechanisms, Mode of Inheritance and Clinical Impact

Clemens Stockklausner, MD^*, Christin Maria Duffert^*, Ziwei Zhou^*, Anne Christine Klotter^*, Isabelle Nadine Kuhlee^* and Andreas E Kulozik, MD PhD

Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany

1635

CCL-2 Is a KIT D816V-Dependent Modulator of Bone Marrow Remodeling and Microenvironmental Alterations in Systemic Mastocytosis

Georg Greiner, MD¹^*, Nadine Witzeneder^1,2^*, Klaus Schmetterer, MD, PhD¹^*, Theresia Popow-Kraupp, MD¹^*, Wolfgang R Sperr, MD^3,4^*, Peter Valent, MD^3,5, Matthias Mayerhofer, MD²^* and Gregor Hoermann, MD, PhD¹^*

¹Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
²Hanusch-Hospital, Ludwig Boltzmann Institute of Osteology, Vienna, Austria
³Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
⁴Ludwig Boltzmann Cluster Oncology, Vienna, Austria
⁵Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria

1636

Metformin Inhibits JAK2V617F Activity By Activating AMPK and PP2A Containing B56 Alpha Subunits in MPN Cells

Ichiro Kawashima, MD¹^* and Keita Kirito, MD²

¹Dept. of Hematology, University of Yamanashi, Yamanashi, Japan
²Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan

1637

Decreased Activity of NK Cells in Myeloproliferative Neoplasms

Adriana Queiroz Arantes, M.D.¹^*, Cristina Tavares Leal, M.D.¹^*, Cleide Araújo Silva¹^*, Priscila Santos Scheucher, Ph.D.¹^*, Aglair Bergamo¹^*, Robert S. Welner, PhD²^*, Daniel G. Tenen, MD^3,4, Ann Mullally, MD⁵, Susumu Kobayashi, MD, PhD², Eduardo Magalhaes Rego, PhD¹ and Lorena Lobo Figueiredo-Pontes, M.D., PhD¹^*

¹Division of Hematology, Department of Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
²Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
³Harvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA, Boston
⁴Cancer Science Institute, National University of Singapore, Singapore, Singapore
⁵Division of Hematology, Brigham and Women's Hospital, Boston, MA

1638

Fishing with a Transgenic Line: Using Zebrafish to Elucidate Mechanisms and Therapeutics in NUP98-NSD1 AML

Corey Filiaggi, BScH¹^*, Adam P Deveau, BScH, MSc²^*, Sergey Prykhozhij, PhD³^*, Graham Dellaire, PhD⁴^* and Jason N. Berman, MD⁵

¹Pathology, Dalhousie University, Halifax, NS, Canada
²Department of Pediatrics, IWK Health Centre, Halifax, NS, Canada
³Department of Pediatrics, Dalhousie University, Halifax, NS, Canada
⁴Pathology and Biochemistry & Molecular Biology, Dalhousie University, Halifax, NS, Canada
⁵Pediatrics/Microbiology and Immunology, IWK Health Centre/Dalhousie University, Halifax, NS, Canada

1639

Possible Role of Impaired Erk1,2 Phosphorilation and Increased sIL2r Alpha Plasma Levels in the Reduced Frequency of Circulating T Regulatory Cells of Patients with Primary Myelofibrosis

Rita Campanelli, BS¹^*, Gabriela Fois, BS¹^*, Carlotta Abbà, BS²^*, Mara De Amici, BS³^*, Laura Villani, BS,¹^*, Elisa Bonetti, PhD¹^*, Paolo Catarsi, BS¹^*, Valentina Poletto, PhD¹^*, Giovanni Barosi, MD¹, Vittorio Rosti, MD¹ and Margherita Massa, PhD⁴^*

¹Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
²IRCCS Policlinico San Matteo Foundation, Biotecnology Research Area, Pavia, Italy
³IRCCS Policlinico San Matteo Foundation, Immuno-Allergy Laboratory of Pediatric Clinic, Pavia, Italy
⁴Biotechnology Research Area, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

See more of: Myeloproliferative Syndromes: Basic Science
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

635.P1.44 635. Myeloproliferative Syndromes: Basic Science: Poster I